Immuneering Corp. (IMRX)
5.02
+0.16
(+3.29%)
USD |
NASDAQ |
Mar 20, 16:00
5.05
+0.03
(+0.60%)
After-Hours: 20:00
Immuneering Research and Development Expense (Quarterly) : 9.194M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Vanda Pharmaceuticals, Inc. | 29.01M |
| Verastem, Inc. | 31.68M |
| Phathom Pharmaceuticals, Inc. | 7.493M |
| Tango Therapeutics, Inc. | 31.62M |
| X4 Pharmaceuticals, Inc. | 18.50M |